ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1322

Cardiopulmonary Involvement in Juvenile Systemic Sclerosis: Development of Recommendations for Screening and Investigation

Ivan Foeldvari1, Clare Pain2, Tamás Constantin3, Eileen Baildam4, Christian Beyer5, Michael Blakley6, Dana Nemkova7 and Clarissa A Pilkington8, 1Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, 2Pediatric Rheumatology, University Children´s Hospital, Liverpool, United Kingdom, 3Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, 4Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, 5Pediatric Cardiology, Hamburg, Germany, 6Internal Medicine and Pediatrics, Indiana University School of Medicine and Riley Hospital for Children at IU Health, Indianapolis, IN, 7Pedaitric Rheumatology, Prague, Czech Republic, 8Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

Meeting: ACR/ARHP Annual Meeting 2014

Keywords: Assessment, Cardiovascular disease, juvenile sclerosis and systemic sclerosis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR)

Session Type: Abstract Submissions (ACR)

Background/Purpose

There are currently no agreed recommendations on how to investigate children for cardiopulmonary involvement in Juvenile Systemic Sclerosis (JSSc). The aim of screening is to detect disease early to facilitate early aggressive therapy and improve outcomes. Cardiopulmonary involvement is the leading cause of death in JSSc and cardiopulmonary involvement at diagnosis incurs a worse outcome (1). Most deaths occur early in the disease course (1, 2).

Objectives  To develop recommendations for investigation of cardiopulmonary in JSSc, based on paediatric evidence and where this was lacking, consensus expert agreement.

Methods

Members of the PRES Scleroderma Working Group were invited to participate; additionally a paediatric cardiologist were invited. A nominal group technique was used. 75% consensus was defined as agreement.

Results

ResultsTable 1 shows the recommendations for screening for cardiopulmonary and GI involvement at baseline and at defined time points from diagnosis. Other recommendations agreed by the group which are relevant at any stage in the disease course are as follows:

  1. If there are any concerns or signs of pulmonary hypertension then right heart catheterisation should be undertaken.
  2. Any child with exertional chest pain or abnormality on 24hr ECG should undergo exercise ECG (if old enough to comply).
  3. Those with worsening PFTS or clinical deterioration should have HRCT thorax repeated sooner (particularly, FVC <70% or DLCO <80% or drop in values by 20% of baseline).

Recommendations are based on low grade evidence and in the most part from expert consensus opinion with extrapolation from adult studies

Table 1. Recommendations for screening for cardiopulmonary and GI involvement in JSSc at baseline and follow-up (75% consensus defined as agreement).

Cardiopulmonary

Baseline

All patients should undergo:

–        BP

–        12 lead ECG

–        24 hour ECG

–        ECHO with Doppler

–        Cardiac MRI with gadolinium

–        HRCT thorax

–        PFT with DLCO

–        6MWT

Follow-up screening (for first 5 years from diagnosis)*

6 monthly

12 lead ECG

ECHO with doppler

6MWT

PFT with DLCO

Annual

24hr ECG

At 3 years

Repeat HRCT

Conclusion

JSSc has a significant mortality particularly early on in the disease course. The objective of an aggressive screening program is to identify cardiopulmonary and GI involvement at a stage which may be amenable to treatment. The recommendations developed by this group aim to standardise care and improve outcomes in this rare disease.


Disclosure:

I. Foeldvari,

Novartis Pharma AG, Abbott, Chugai, Genzyme,

5;

C. Pain,
None;

T. Constantin,
None;

E. Baildam,
None;

C. Beyer,
None;

M. Blakley,
None;

D. Nemkova,
None;

C. A Pilkington,
None.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2014

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiopulmonary-involvement-in-juvenile-systemic-sclerosis-development-of-recommendations-for-screening-and-investigation/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology